SGLT-2-Inhibition mit Canagliflozin: Eine neue Option in der Therapie des Typ-2-Diabetes

Schlüsselwörter

SGLT-2-Inhibitor - Canagliflozin - Typ-2-Diabetes - kardiovaskuläres Risiko - Glykämiekontrolle - therapeutische Glukosurie

Keywords

SGLT-2 inhibitor - canagliflozin - type 2 diabetes - cardiovascular risk - glycaemic control - therapeutical glucosuria

• Literatur

• 1 Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013; 27: 280-286
• 2 Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009; 25: 671-681
• 3 Berthold HK, Gouni-Berthold I, Bestehorn K et al. Kardiovaskuläre Risikofaktoren bei Typ-2-Diabetikern in Deutschland – ein Versorgungsparadox. Dtsch Arztebl 2007; 104: A 861-867
• 4 Bode B, Stenlöf K, Sullivan D et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) 2013; 41: 72-84
• 5 Cefalu WT, Leiter LA, Yoon KH et al. Canagliflozin (CANA) Demonstrates Durable Glycemic Improvements Over 104 Weeks versus Glimepiride (GLIM) in Subjects with Type 2 Diabetes Mellitus (T2DM) on Metformin (MET). Diabetes 2013; 62 (Suppl. 01) 65-LB
• 6 Cefalu WT, Leiter LA, Yoon KH et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950
• 7 DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 2009; 58: 773-795
• 8 DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14: 5-14
• 9 Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus. J Clin Pharmacol 2013; 53: 601-610
• 10 Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545
• 11 Emerging Risk Factors Collaboration. . Sarwar N, Gao P et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222
• 12 . http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf (letzter Zugriff 11.12.2013)
• 13 Gerich J. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-142
• 14 Hauner H, Hanisch J, Bramlage P et al. Prevalence of undiagnosed Type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Exp Clin Endocrinol Diabetes 2008; 116: 18-25
• 15 Hummel CS, Lu C, Liu J et al. Structural selectivity of human SGLT inhibitors. Am J Physiol Cell Physiol 2012; 302: C373-382
• 16 Huppertz E, Pieper L, Klotsche J et al. Diabetes Mellitus in German Primary Care: Quality of Glycaemic Control and Subpopulations not well Controlled – Results of the DETECT Study. Exp Clin Endocrinol Diabetes 2009; 117: 6-14
• 17 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
• 18 Janssen Briefing Information.. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf (letzter Zugriff 11.12.2013)
• 19 Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592
• 20 Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555
• 21 Maeda S, Matsui T, Takeuchi M et al. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products (AGEs)-induced tubular cell apoptosis. Diabetes Metab Res Rev 2013; 29: 406-412
• 22 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
• 23 Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 6355-6360
• 24 Panchapakesan U, Pegg K, Gross S et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells – renoprotection in diabetic nephropathy?. PLoS One 2013; 8: e54442
• 25 Rahmoune H, Thompson PW, Ward JM. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434
• 26 Rosenstock J, Davies MJ, Dumas R et al. Effects of Canagliflozin Added on to Basal Insulin +/- Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes 2013; 62 (Suppl. 01) 1084-P
• 27 Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-141
• 28 Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial. Diabetes Care 2013; 36: 2508-2515
• 29 Seufert J. Kardiovaskuläre Endpunktstudien in der Therapie des Typ-2-Diabetes-mellitus. Dtsch Arztebl 2006; 103: A 934-942
• 30 Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672
• 31 Stenlöf K, Cefalu WT, Kim KA et al. Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks. Diabetes 2013; 62 (Suppl. 01) 1164-P
• 32 Stenlöf K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382
• 33 Weir M, Januszewicz A, Gilbert RE et al. Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM). Diabetes 2013; 62 (Suppl. 01) 1077-P
• 34 Weissenbacher ER, Autenrieth M, Bauer HW et al. Konsens für Therapieempfehlungen von Urogenitalinfektionen bei Typ-2-Diabetikern. Diabetes Stoffw Herz 2012; 21: 179-184
• 35 Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10-18
• 36 Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43